Office Of The Governor Statement On COVID-19 Monoclonal Antibody Treatment

67

Translate to Spanish or other 102 languages!

overnor Abbott’s doctor prescribed Regeneron's monoclonal antibody therapy treatment, which is available at no cost to all Texans who get a doctor’s referral. Image for illustration purposes
Governor Abbott’s doctor prescribed Regeneron’s monoclonal antibody therapy treatment, which is available at no cost to all Texans who get a doctor’s referral. Image for illustration purposes

Mega Doctor News

- Advertisement -

AUSTIN – Office of the Governor Communications Director Mark Miner today issued the following statement:

“Governor Abbott’s doctor prescribed Regeneron’s monoclonal antibody therapy treatment, which is available at no cost to all Texans who get a doctor’s referral. It is recommended that Texans testing positive for COVID-19 seek this antibody therapeutic drug because of its effectiveness to help keep people out of hospitals. Today, the Governor announced the continued expansion of COVID-19 Antibody Infusion Centers across Texas. That is in addition to more than 140 providers that are providing antibody treatment at hospitals and clinics across the state.”

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Local coalition encourages everyone to “Stomp Out Tobacco” with 5K run
Next article
More COVID-19 Antibody Infusion Centers Throughout Texas On The Way

More Articles

DHR Health Raises Over $520K at 20th “Fishing for Hope” Event

DHR Health made a big splash at the 20th Annual “Fishing for Hope” Tournament, held on August 22 at Jim’s Pier in South Padre Island, raising an impressive grand total of $524,130.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 

Moderna and Merck Report Positive Phase 3 Results for Personalized Cancer Therapy

Moderna and Merck have reached a major clinical milestone after their investigational individualized cancer therapy, combined with Merck’s Keytruda, produced positive results in a Phase 3 study involving patients with high-risk melanoma.

STHS Scores Fourth Consecutive 5-Star Rating for Diabetic Care

Diabetes remains one of the nation’s most pressing health challenges, with a disease once largely associated with older adults now affecting younger populations at an alarming rate.
- Advertisement -